Skip to main content

Table 2 Baseline patient characteristics among stage III patients comprising the retrospective cohort

From: Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis

 

Vaccine

No Adjuvant

 
 

N = 67

N = 123

 
 

N(%)/Mean(SD)

N(%)/Mean(SD)

P-Value

Age

56.00 (13.44)

60.05 (16.44)

0.086

Sex

  

0.2854

 Female

31 (46.27)

47 (38.21)

 

 Male

36 (53.73)

76 (61.79)

 

Thicknessa

3.12 (4.43)

4.18 (4.46)

0.009

Ulceration

  

0.3511

 Present

23 (34.33)

52 (42.28)

 

 Absent

32 (47.76)

57 (46.34)

 

 Undetermined

12 (17.91)

14 (11.38)

 

AJCC Stage

  

0.0082

 IIIA

15 (22.39)

48 (39.02)

 

 IIIB

26 (38.81)

51 (41.46)

 

 IIIC

26 (38.81)

24 (19.51)

 

Histologic Subtype

  

0.0435

 Nodular

17 (25.37)

52 (42.28)

 

 Superficial Spreading

12 (17.91)

26 (21.14)

 

 Other

6 (8.96)

13 (10.57)

 

 Undetermined

32 (47.76)

32 (26.02)

 

Other Adjuvant Treatment

  

–

 GM-CSF

6 (8.96)

Not Applicable

 

 Interferon

6 (8.96)

 

 Isolated Limb Infusion

3 (4.48)

 

 Radiation

22 (32.84)

 
  1. amissing values for thickness: vaccine: 10; no adjuvant: 13
  2. athickness not normally-distributed, log-transformed for statistical test